Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, Felip E, Garon EB, Audhuy F, Ito R, Sato M, Eggleton SP, Martin CM, Reck M, Robinson CG, Paz-Ares L. Vokes EE, et al. Among authors: cil t. J Thorac Oncol. 2024 Feb;19(2):285-296. doi: 10.1016/j.jtho.2023.09.1452. Epub 2023 Oct 4. J Thorac Oncol. 2024. PMID: 37797733 Free article. Clinical Trial.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Among authors: cil t. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Chen L, Rangel JDG, Cil T, Li X, Cicin I, Shen Y, Liu Z, Ozyilkan O, Igor B, Chen J, Oleksandr K, Chen Z, Zhang H, Fu Z, Dong Q, Song S, Yu JC, Zhang L. Chen L, et al. Among authors: cil t. Cancer Med. 2023 Nov;12(22):20847-20863. doi: 10.1002/cam4.6664. Epub 2023 Nov 7. Cancer Med. 2023. PMID: 37935428 Free PMC article. Clinical Trial.
Brigatinib-associated autoimmune hepatitis: A case report.
Buyuksimsek M, Ogul A, Yetisir AE, Duman BB, Tohumcuoglu M, Cil T, Koseci T, Kidi MM, Sumbul HE. Buyuksimsek M, et al. Among authors: cil t. J Oncol Pharm Pract. 2023 Apr 18:10781552231171322. doi: 10.1177/10781552231171322. Online ahead of print. J Oncol Pharm Pract. 2023. PMID: 37073439
The Canadian Breast Cancer Symposium 2023 Meeting Report.
Cil T, Boileau JF, Chia S, DeCoteau MJ, Jerzak KJ, Koch A, Nixon N, Quan ML, Roberts A, Brezden-Masley C. Cil T, et al. Curr Oncol. 2024 Mar 29;31(4):1774-1802. doi: 10.3390/curroncol31040135. Curr Oncol. 2024. PMID: 38668038 Free PMC article.
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.
Yildirim ME, Karadurmuş N, Ökten İN, Türk HM, Urakçı Z, Arslan Ç, Çelik S, Dane F, Şendur MAN, Bilir C, Karabulut B, Cicin İ, Çubukçu E, Karaca M, Ozcelik M, Artaç M, Tanrikulu E, Alacacioglu A, Açıkgöz Ö, Öven B, Geredeli Ç, Çil T, Harputluoğlu H, Kefeli U, Bozkurt O, Tural D, Sakin A, Yalçın Ş, Gumus M. Yildirim ME, et al. Among authors: cil t. J Oncol Pharm Pract. 2024 Apr 13:10781552241241004. doi: 10.1177/10781552241241004. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 38613329
2023 Canadian Surgery Forum: Sept. 20-23, 2023.
Brière R, Émond M, Benhamed A, Blanchard PG, Drolet S, Habashi R, Golbon B, Shellenberger J, Pasternak J, Merchant S, Shellenberger J, La J, Sawhney M, Brogly S, Cadili L, Horkoff M, Ainslie S, Demetrick J, Chai B, Wiseman K, Hwang H, Alhumoud Z, Salem A, Lau R, Aw K, Nessim C, Gawad N, Alibhai K, Towaij C, Doan D, Raîche I, Valji R, Turner S, Balmes PN, Hwang H, Hameed SM, Tan JGK, Wijesuriya R, Tan JGK, Hew NLC, Wijesuriya R, Lund M, Hawel J, Gregor J, Leslie K, Lenet T, McIsaac D, Hallet J, Jerath A, Lalu M, Nicholls S, Presseau J, Tinmouth A, Verret M, Wherrett C, Fergusson D, Martel G, Sharma S, McKechnie T, Talwar G, Patel J, Heimann L, Doumouras A, Hong D, Eskicioglu C, Wang C, Guo M, Huang L, Sun S, Davis N, Wang J, Skulsky S, Sikora L, Raîche I, Son HJ, Gee D, Gomez D, Jung J, Selvam R, Seguin N, Zhang L, Lacaille-Ranger A, Sikora L, McIsaac D, Moloo H, Follett A, Holly, Organ M, Pace D, Balvardi S, Kaneva P, Semsar-Kazerooni K, Mueller C, Vassiliou M, Al Mahroos M, Fiore JF Jr, Schwartzman K, Feldman L, Guo M, Karimuddin A, Liu GP, Crump T, Sutherland J, Hickey K, Bonisteel EM, Umali J, Dogar I, Warden G, Boone D, Mathieson A, Hogan M, Pace D, Seguin N, Moloo H, Li Y, Be… See abstract for full author list ➔ Brière R, et al. Among authors: cil t. Can J Surg. 2023 Dec 13;66(6 Suppl 1):S54-S136. doi: 10.1503/cjs.014223. Print 2023 Nov-Dec. Can J Surg. 2023. PMID: 38173057 Free PMC article. No abstract available.
C-CASE 2023: Promoting Excellence in Surgical Education: Canadian Conference for the Advancement of Surgical Education, Oct. 12-13, 2023, Montréal, Quebec.
Sioufi J, Hall B, Antel R, Moussa S, Subasri M, Fakih M, Islam N, Hamdy RC, Chopra S, Harley JM, Keuhl A, Bassilious E, Sherbino J, Bilgic E, Bondok MS, Bondok M, Martel L, Law C, Posel N, Fleiszer D, Daud A, Hauer T, Carr-Pries N, Hali K, Wolfstadt J, Ferguson P, Ghasroddashti A, Sorefan-Mangou F, Del Fernandes R, Williams E, Choi K, Zevin B, Patterson ED, Kirupaharan S, Mann S, Winthrop A, Zevin B, Bondok M, Ghanmi N, Etherington C, Saddiki Y, Lefebvre I, Berthelot P, Dion PM, Raymond B, Seguin J, Sekhavati P, Islam S, Boet S, Tee T, Pachchigar P, Tarabay B, Yilmaz R, Hamdan NA, Agu C, Almansouri A, Harley J, Del Maestro R, Bondok M, Bondok MS, Nguyen AX, Law C, Nathoo N, Bakshi N, Ahuja N, Damji KF, Grewal K, Azher S, Moreno M, Pekrun R, Wiseman J, Fried GM, Lajoie S, Brydges R, Hadwin A, Sun NZ, Khalil E, Harley JM, Nguyen EL, Patel P, Muaddi H, Rukavina N, Bucur R, Shwaartz C, Islam N, Moussa S, Subasri M, Fakih M, Hamdy RC, Wong E, Tewari A, Brydges R, Louridas M, Balaji S, Patel P, Muaddi H, Gaebe K, Luzzi C, Kay A, Rukavina N, Selzner M, Reichman T, Shwaartz C, Balaji S, Muaddi H, Shahabinezhad A, Patel P, Rukavina N, Reichman T, Jayaraman S, Shwaartz C, Nashed J, Ramelli … See abstract for full author list ➔ Sioufi J, et al. Among authors: cil t. Can J Surg. 2023 Dec 8;66(6 Suppl 2):S137-S150. doi: 10.1503/cjs.014523. Print 2023 Nov-Dec. Can J Surg. 2023. PMID: 38065582 Free PMC article. No abstract available.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
136 results